ATE454372T1 - Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen - Google Patents
Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungenInfo
- Publication number
- ATE454372T1 ATE454372T1 AT05730691T AT05730691T ATE454372T1 AT E454372 T1 ATE454372 T1 AT E454372T1 AT 05730691 T AT05730691 T AT 05730691T AT 05730691 T AT05730691 T AT 05730691T AT E454372 T1 ATE454372 T1 AT E454372T1
- Authority
- AT
- Austria
- Prior art keywords
- histamine
- receptor
- production
- therapeutic applications
- agents active
- Prior art date
Links
- 102000004384 Histamine H3 receptors Human genes 0.000 title abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 1
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55854204P | 2004-04-01 | 2004-04-01 | |
| US61710104P | 2004-10-08 | 2004-10-08 | |
| PCT/US2005/010240 WO2005097740A1 (en) | 2004-04-01 | 2005-03-25 | Histamine h3 receptor agents, preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE454372T1 true ATE454372T1 (de) | 2010-01-15 |
Family
ID=34964070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05730691T ATE454372T1 (de) | 2004-04-01 | 2005-03-25 | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7632857B2 (de) |
| EP (1) | EP1735278B1 (de) |
| JP (1) | JP4777974B2 (de) |
| CN (1) | CN1960969B (de) |
| AT (1) | ATE454372T1 (de) |
| AU (1) | AU2005230881B9 (de) |
| BR (1) | BRPI0509298A (de) |
| CA (1) | CA2561628C (de) |
| CY (1) | CY1109860T1 (de) |
| DE (1) | DE602005018758D1 (de) |
| DK (1) | DK1735278T3 (de) |
| ES (1) | ES2337376T3 (de) |
| MX (1) | MXPA06011167A (de) |
| PL (1) | PL1735278T3 (de) |
| PT (1) | PT1735278E (de) |
| SI (1) | SI1735278T1 (de) |
| WO (1) | WO2005097740A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008301B2 (en) * | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| CN101006082B (zh) | 2004-08-23 | 2010-09-29 | 伊莱利利公司 | 组胺h3受体药剂、制备方法和治疗用途 |
| GT200600042A (es) * | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
| AU2006232871B9 (en) * | 2005-04-01 | 2011-11-24 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| MX2007016216A (es) * | 2005-07-01 | 2008-03-11 | Lilly Co Eli | Agenes del receptor de histamina h3, preparacion y usos terapeuticos. |
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| ES2381205T3 (es) | 2005-11-10 | 2012-05-24 | Msd K.K. | Derivado espiro aza-sustituido |
| AU2006314649A1 (en) | 2005-11-18 | 2007-05-24 | F. Hoffmann-La Roche Ag | Azaindole-2-carboxamide derivatives |
| ES2344077T3 (es) * | 2005-12-16 | 2010-08-17 | F.Hoffmann-La Roche Ag | Derivados de pirrolo(2,3-b)piridina como moduladores del receptor h3. |
| EP1994022A2 (de) * | 2006-03-15 | 2008-11-26 | Wyeth a Corporation of the State of Delaware | N-substituierte azacyclylamine als histamin-3-antagonisten |
| WO2008005338A1 (en) * | 2006-06-29 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| TW200823204A (en) * | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
| CA2687721A1 (en) * | 2007-06-08 | 2008-12-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| RU2010116821A (ru) * | 2007-10-01 | 2011-11-10 | Ф.Хоффманн-Ля Аг (Ch) | N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr |
| EP2752406A1 (de) * | 2008-01-30 | 2014-07-09 | Cephalon, Inc. | Substituierte Pyridazinderivate mit Histamin-H3-Antagonistenaktivität |
| US9079888B2 (en) * | 2011-02-23 | 2015-07-14 | Suven Life Sciences Limited | Compounds as histamine H3 receptor ligands |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EP2867236B1 (de) | 2012-06-29 | 2017-06-14 | Pfizer Inc | Neue 4-(substituierte amino)-7h-pyrrolo[2,3-d]pyrimidine als lrrk2 hemmer |
| ES2753386T3 (es) | 2013-03-13 | 2020-04-08 | Forma Therapeutics Inc | Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer |
| EP3083618B1 (de) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Neuartige 3,4-disubstituierte-1h-pyrrolo[2,3-b]pyridine und 4,5-disubstituierte 7h-pyrrolo[2,3-c]pyridazine als lrrk2-hemmer |
| JP6633618B2 (ja) * | 2014-08-21 | 2020-01-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体 |
| PL3303330T3 (pl) | 2015-06-03 | 2019-10-31 | Bristol Myers Squibb Co | Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych |
| EP3319968A1 (de) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclische n-aminophenyl-amide als inhibitoren der histondeacetylase |
| WO2017007756A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc | Hetero-halo inhibitors of histone deacetylase |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| HUE057849T2 (hu) | 2017-01-11 | 2022-06-28 | Alkermes Inc | Hiszton deacetiláz biciklusos gátlói |
| LT3664802T (lt) | 2017-08-07 | 2022-06-27 | Alkermes, Inc. | Bicikliniai histonų deacetilazės inhibitoriai |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| US12577211B2 (en) | 2020-06-29 | 2026-03-17 | Bacainn Biotherapeutics, Ltd. | Probenecid compounds for the treatment of inflammasome-mediated lung disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2579596B1 (fr) | 1985-03-26 | 1987-11-20 | Inst Nat Sante Rech Med | (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique |
| FR2671083B1 (fr) | 1990-12-31 | 1994-12-23 | Inst Nat Sante Rech Med | Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques. |
| DE69619381T2 (de) | 1995-05-30 | 2002-11-21 | Gliatech, Inc. | 1h-4(5)substituierte imidazolderivate |
| US5652258A (en) | 1995-05-30 | 1997-07-29 | Gliatech, Inc. | 2-(4-imidazoyl) cyclopropyl derivatives |
| WO1997029092A1 (en) | 1996-02-09 | 1997-08-14 | James Black Foundation Limited | Histamine h3 receptor ligands |
| US6620839B2 (en) * | 2000-07-13 | 2003-09-16 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| JP2004532834A (ja) * | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| CN1625554A (zh) * | 2002-02-01 | 2005-06-08 | 诺沃挪第克公司 | 氨基烷基－取代的氮杂环丁烷、吡咯烷、哌啶与氮杂环庚烷的酰胺 |
| DK1603570T5 (da) * | 2003-02-26 | 2013-12-09 | Sugen Inc | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
| EP1720861A2 (de) | 2004-02-25 | 2006-11-15 | Eli Lilly And Company | Antagonisten des histamin-h3-rezeptors, herstellung und therapeutische anwendungen |
-
2005
- 2005-03-25 BR BRPI0509298-1A patent/BRPI0509298A/pt not_active IP Right Cessation
- 2005-03-25 DK DK05730691.2T patent/DK1735278T3/da active
- 2005-03-25 DE DE602005018758T patent/DE602005018758D1/de not_active Expired - Lifetime
- 2005-03-25 PT PT05730691T patent/PT1735278E/pt unknown
- 2005-03-25 CN CN2005800171466A patent/CN1960969B/zh not_active Expired - Lifetime
- 2005-03-25 JP JP2007506412A patent/JP4777974B2/ja not_active Expired - Fee Related
- 2005-03-25 MX MXPA06011167A patent/MXPA06011167A/es active IP Right Grant
- 2005-03-25 EP EP05730691A patent/EP1735278B1/de not_active Expired - Lifetime
- 2005-03-25 ES ES05730691T patent/ES2337376T3/es not_active Expired - Lifetime
- 2005-03-25 SI SI200530961T patent/SI1735278T1/sl unknown
- 2005-03-25 AU AU2005230881A patent/AU2005230881B9/en not_active Ceased
- 2005-03-25 WO PCT/US2005/010240 patent/WO2005097740A1/en not_active Ceased
- 2005-03-25 CA CA2561628A patent/CA2561628C/en not_active Expired - Fee Related
- 2005-03-25 AT AT05730691T patent/ATE454372T1/de active
- 2005-03-25 US US10/599,488 patent/US7632857B2/en not_active Expired - Fee Related
- 2005-03-25 PL PL05730691T patent/PL1735278T3/pl unknown
-
2010
- 2010-02-25 CY CY20101100183T patent/CY1109860T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005230881B2 (en) | 2011-03-31 |
| CN1960969B (zh) | 2012-03-28 |
| AU2005230881B9 (en) | 2011-08-25 |
| ES2337376T3 (es) | 2010-04-23 |
| SI1735278T1 (sl) | 2010-05-31 |
| MXPA06011167A (es) | 2007-01-25 |
| CA2561628A1 (en) | 2005-10-20 |
| PL1735278T3 (pl) | 2010-06-30 |
| US7632857B2 (en) | 2009-12-15 |
| EP1735278A1 (de) | 2006-12-27 |
| EP1735278B1 (de) | 2010-01-06 |
| DE602005018758D1 (de) | 2010-02-25 |
| BRPI0509298A (pt) | 2007-09-18 |
| AU2005230881A1 (en) | 2005-10-20 |
| DK1735278T3 (da) | 2010-04-12 |
| CA2561628C (en) | 2012-05-08 |
| CY1109860T1 (el) | 2014-09-10 |
| PT1735278E (pt) | 2010-03-09 |
| JP2007530698A (ja) | 2007-11-01 |
| JP4777974B2 (ja) | 2011-09-21 |
| CN1960969A (zh) | 2007-05-09 |
| US20070208024A1 (en) | 2007-09-06 |
| WO2005097740A1 (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE454372T1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
| ATE445609T1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
| NO20070213L (no) | Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| BRPI0517438A (pt) | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| TW200800946A (en) | Substituted piperazines as metabotropic glutamate receptor antagonists | |
| ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| CY1110453T1 (el) | Αναστολεις υποδοχεα η3 ισταμινης, παρασκευη και θεραπευτικες χρησεις | |
| ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1735278 Country of ref document: EP |